{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:42:40Z","timestamp":1792658560956,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To review the current evidence on anticoagulation for intracranial haemorrhage (ICrH) survivors with atrial fibrillation (AF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Narrative review of the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>AF and ICrH are age-related conditions whose prevalence and comorbidity is expected to increase with the ageing population. Patients with ICrH were excluded from pivotal randomized trials of anticoagulation in AF and guidelines do not provide strong recommendations on if and when to (re)initiate anticoagulation in patients with AF and ICrH. Pooled analyses of phase II randomized trials have reported reduced risk of ischaemic major adverse cardiovascular events with anticoagulation in this population, but there remains uncertainty regarding the effects of anticoagulation on recurrent ICrH and death, as well as potential heterogeneity of treatment effect in higher risk subgroups, such as patients with cerebral amyloid angiopathy. There are no reported randomized trials investigating the optimal timing of anticoagulation (re)initiation in ICrH survivors with AF and the findings from observational studies have been inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Whether or not OAC should be resumed in ICrH survivors with AF and the optimal timing of OAC (re)initiation are challenging clinical dilemmas that are becoming more frequent with our ageing population. The existing prevalence of AF in patients with ICrH and changing global demographics highlight the importance of ongoing and future randomized trials addressing unresolved questions surrounding optimal stroke prevention strategies in this vulnerable patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873241296803","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:00:24Z","timestamp":1747897224000},"page":"35-45","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Oral Anticoagulation following intracranial haemorrhage in patients with atrial fibrillation"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2802-1626","authenticated-orcid":false,"given":"Ashkan","family":"Shoamanesh","sequence":"first","affiliation":[{"name":"Department of Medicine (Neurology), Population Health Research Institute, McMaster University, Hamilton, ON, Canada 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-4578","authenticated-orcid":false,"given":"Catharina JM","family":"Klijn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Centre, Nijmegen, Netherlands 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin N","family":"Sheth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, CT, USA 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Veltkamp","sequence":"additional","affiliation":[{"name":"Department of Brain Sciences, Imperial College London, London, UK 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4312-4778","authenticated-orcid":false,"given":"Else C","family":"Sandset","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital and the Norwegian Air Ambulance Foundation, Oslo, Norway 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cordonnier","sequence":"additional","affiliation":[{"name":"University of Lille, Inserm, CHU Lille, U1172 \u2013 LilNCog \u2013 Lille Neuroscience & Cognition, Lille, France 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2108-9222","authenticated-orcid":false,"given":"Rustam","family":"Al-Shahi Salman","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK 7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026012113080845700_bibr1-23969873241296803","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ana.26184","article-title":"Reply to \u201cPrior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation\u201d","volume":"90","author":"Meinel","year":"2021","journal-title":"Ann Neurol"},{"key":"2026012113080845700_bibr2-23969873241296803","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","article-title":"Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: Insights from the NCDR PINNACLE Registry","volume":"1","author":"Hsu","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012113080845700_bibr3-23969873241296803","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0149-2918(03)80167-4","article-title":"Factors influencing physicians\u2019 reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey","volume":"25","author":"Gross","year":"2003","journal-title":"Clin Ther"},{"key":"2026012113080845700_bibr4-23969873241296803","doi-asserted-by":"crossref","first-page":"e0191137","DOI":"10.1371\/journal.pone.0191137","article-title":"Correction: oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts","volume":"13","author":"Xu","year":"2018","journal-title":"PLoS One"},{"key":"2026012113080845700_bibr5-23969873241296803","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1747493020968424","article-title":"Canadian stroke best practice recommendations: management of spontaneous intracerebral hemorrhage, 7th Edition Update 2020","volume":"16","author":"Shoamanesh","year":"2021","journal-title":"Int J Stroke"},{"key":"2026012113080845700_bibr6-23969873241296803","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke"},{"key":"2026012113080845700_bibr7-23969873241296803","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026012113080845700_bibr8-23969873241296803","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026012113080845700_bibr9-23969873241296803","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1055\/a-1789-4824","article-title":"Managing Uncertainty: physicians\u2019 decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage","volume":"122","author":"Ivany","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026012113080845700_bibr10-23969873241296803","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1161\/STROKEAHA.114.006202","article-title":"Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage","volume":"45","author":"Pasquini","year":"2014","journal-title":"Stroke"},{"key":"2026012113080845700_bibr11-23969873241296803","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.08.017","article-title":"Nationwide survey of neuro-specialists\u2019 opinions on anticoagulant therapy after intracerebral hemorrhage in patients with atrial fibrillation","volume":"312","author":"Maeda","year":"2012","journal-title":"J Neurol Sci"},{"key":"2026012113080845700_bibr12-23969873241296803","article-title":"Non-vitamin K oral anticoagulants in intracerebral hemorrhage survivors with atrial fibrillation: primary results of the NASPAF-ICH randomized trial","author":"Shoamanesh","year":"2020"},{"key":"2026012113080845700_bibr13-23969873241296803","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1474-4422(21)00298-2","article-title":"Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial","volume":"20","author":"Schreuder","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr14-23969873241296803","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S1474-4422(21)00264-7","article-title":"Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial","volume":"20","author":"Collaboration","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr15-23969873241296803","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104351","article-title":"Comorbid atrial fibrillation in cerebral amyloid angiopathy-related intracerebral hemorrhage: between a rock and a hard Place","volume":"28","author":"Shoamanesh","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026012113080845700_bibr16-23969873241296803","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1161\/STROKEAHA.113.001263","article-title":"Differences in outcome and predictors between ischemic and intracerebral hemorrhage: the South London Stroke Register","volume":"44","author":"Bhalla","year":"2013","journal-title":"Stroke"},{"key":"2026012113080845700_bibr17-23969873241296803","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/STROKEAHA.116.012945","article-title":"Use of antithrombotic therapy and long-term clinical outcome among patients surviving intracerebral hemorrhage","volume":"47","author":"Ottosen","year":"2016","journal-title":"Stroke"},{"key":"2026012113080845700_bibr18-23969873241296803","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.09.021","article-title":"Association between seizures and outcomes among intracerebral hemorrhage patients: the China National Stroke Registry","volume":"24","author":"Li","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026012113080845700_bibr19-23969873241296803","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000475667","article-title":"Comparisons of risk factors for intracerebral hemorrhage versus ischemic stroke in Chinese patients","volume":"48","author":"Tsai","year":"2017","journal-title":"Neuroepidemiology"},{"key":"2026012113080845700_bibr20-23969873241296803","doi-asserted-by":"crossref","first-page":"100842","DOI":"10.1016\/j.lanepe.2024.100842","article-title":"Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050","volume":"38","author":"Wafa","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026012113080845700_bibr21-23969873241296803","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int J Stroke"},{"key":"2026012113080845700_bibr22-23969873241296803","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.031","article-title":"Type 2 diabetes and hemorrhagic stroke: a population-based study in Spain from 2003 to 2012","volume":"25","author":"Mu\u00f1oz-Rivas","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2026012113080845700_bibr23-23969873241296803","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(23)00315-0","article-title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials","volume":"22","author":"Al-Shahi Salman","year":"2023","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr24-23969873241296803","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"2026012113080845700_bibr25-23969873241296803","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026012113080845700_bibr26-23969873241296803","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral anticoagulation and functional outcome after intracerebral hemorrhage","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"2026012113080845700_bibr27-23969873241296803","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/STROKEAHA.118.024449","article-title":"Five-year risk of major ischemic and hemorrhagic events after intracerebral hemorrhage","volume":"50","author":"Casolla","year":"2019","journal-title":"Stroke"},{"key":"2026012113080845700_bibr28-23969873241296803","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2214-109X(20)30069-3","article-title":"Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0\u00b75 million Chinese adults","volume":"8","author":"Chen","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2026012113080845700_bibr29-23969873241296803","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/2396987320953394","article-title":"Long-term prognosis after intracerebral haemorrhage","volume":"5","author":"van Nieuwenhuizen","year":"2020","journal-title":"Eur Stroke J"},{"key":"2026012113080845700_bibr30-23969873241296803","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/STROKEAHA.119.026207","article-title":"Risk of arterial ischemic events after intracerebral hemorrhage","volume":"51","author":"Murthy","year":"2020","journal-title":"Stroke"},{"key":"2026012113080845700_bibr31-23969873241296803","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/jamaneurol.2021.0925","article-title":"Association between intracerebral hemorrhage and subsequent arterial ischemic events in participants from 4 population-based cohort studies","volume":"78","author":"Murthy","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026012113080845700_bibr32-23969873241296803","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1474-4422(21)00075-2","article-title":"Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies","volume":"20","author":"Li","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr33-23969873241296803","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1212\/WNL.0000000000004259","article-title":"Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"key":"2026012113080845700_bibr34-23969873241296803","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1747493019830065","article-title":"Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: large prospective cohort and preliminary meta-analysis","volume":"14","author":"Charidimou","year":"2019","journal-title":"Int J Stroke"},{"key":"2026012113080845700_bibr35-23969873241296803","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.56.6.773","article-title":"Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage","volume":"56","author":"Bailey","year":"2001","journal-title":"Neurology"},{"key":"2026012113080845700_bibr36-23969873241296803","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00415-021-10706-3","article-title":"Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis","volume":"269","author":"Hostettler","year":"2022","journal-title":"J Neurol"},{"key":"2026012113080845700_bibr37-23969873241296803","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/WNL.0000000000003281","article-title":"Cortical superficial siderosis predicts early recurrent lobar hemorrhage","volume":"87","author":"Roongpiboonsopit","year":"2016","journal-title":"Neurology"},{"key":"2026012113080845700_bibr38-23969873241296803","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"2026012113080845700_bibr39-23969873241296803","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"2026012113080845700_bibr40-23969873241296803","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026012113080845700_bibr41-23969873241296803","article-title":"Antithrombotic treatment after stroke due to intracerebral haemorrhage","volume":"1","author":"Cochrane","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012113080845700_bibr42-23969873241296803","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"New Engl J Med"},{"key":"2026012113080845700_bibr43-23969873241296803","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(23)02025-1","article-title":"Anticoagulation in patients with cerebral amyloid angiopathy","volume":"402","author":"Shoamanesh","year":"2023","journal-title":"Lancet"},{"key":"2026012113080845700_bibr44-23969873241296803","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/j.1538-7836.2010.03882.x","article-title":"Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk","volume":"8","author":"Hawryluk","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026012113080845700_bibr45-23969873241296803","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.joa.2017.05.004","article-title":"2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation","volume":"33","author":"Chiang","year":"2017","journal-title":"J Arrhythm"},{"key":"2026012113080845700_bibr46-23969873241296803","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113080845700_bibr47-23969873241296803","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026012113080845700_bibr48-23969873241296803","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/STROKEAHA.116.014643","article-title":"Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation","volume":"48","author":"Pennlert","year":"2017","journal-title":"Stroke"},{"key":"2026012113080845700_bibr49-23969873241296803","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.hrthm.2016.05.016","article-title":"Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage","volume":"13","author":"Park","year":"2016","journal-title":"Heart Rhythm"},{"key":"2026012113080845700_bibr50-23969873241296803","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"key":"2026012113080845700_bibr51-23969873241296803","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","author":"Collaborators GBDS; GBD 2019 Stroke Collaborators","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr52-23969873241296803","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S1474-4422(14)70031-6","article-title":"Acute post-stroke blood pressure relative to premorbid levels in intracerebral haemorrhage versus major ischaemic stroke: a population-based study","volume":"13","author":"Fischer","year":"2014","journal-title":"Lancet Neurol"},{"key":"2026012113080845700_bibr53-23969873241296803","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jama.2015.10082","article-title":"Association between blood pressure control and risk of recurrent intracerebral hemorrhage","volume":"314","author":"Biffi","year":"2015","journal-title":"JAMA"},{"key":"2026012113080845700_bibr54-23969873241296803","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/STROKEAHA.109.563932","article-title":"Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial","volume":"41","author":"Arima","year":"2010","journal-title":"Stroke"},{"key":"2026012113080845700_bibr55-23969873241296803","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2147\/CIA.S335321","article-title":"Average systolic blood pressure and clinical outcomes in patients with atrial fibrillation: prospective data from COOL-AF Registry","volume":"16","author":"Krittayaphong","year":"2021","journal-title":"Clin Interv Aging"},{"key":"2026012113080845700_bibr56-23969873241296803","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"2026012113080845700_bibr57-23969873241296803","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","article-title":"Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation","volume":"45","author":"Hankey","year":"2014","journal-title":"Stroke"},{"key":"2026012113080845700_bibr58-23969873241296803","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jocn.2020.10.036","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: an in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial","volume":"86","author":"Nelson","year":"2021","journal-title":"J Clin Neurosci"},{"key":"2026012113080845700_bibr59-23969873241296803","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2016-08-731638","article-title":"Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy","volume":"129","author":"Lopes","year":"2017","journal-title":"Blood"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873241296803","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873241296803","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/35\/64645591\/23969873241296803.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/35\/64645591\/23969873241296803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:40Z","timestamp":1769018920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1_suppl\/35\/8268617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":59,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873241296803","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2025,4,1]]}}}